. 2019 Feb 6;8(3):239–251. doi: 10.1530/EC-18-0485
This work is licensed under a Table 2.
Overall survival rates and cancer-specific survival of patients with PNETs stratified by surgery or not.
| Characteristic | Levels | OS | Median survival time (months) | P | Hazard ratio (95% CI) | CSS | Median survival time (months) | P | Hazard ratio (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 2-year | 3-year | 1-year | 2-year | 3-year | |||||||||
| Whole cohort | No surgery | 46.0 | 30.8 | 23.0 | 10 | <0.001 | 3.17 (2.81–3.58) | 47.6 | 32.6 | 24.6 | 11 | <0.001 | 3.28 (2.89–3.71) | |
| Surgery | 85.4 | 75.4 | 67.1 | 68 | 85.8 | 76.1 | 68.6 | 71 | ||||||
| Age (years) | ≤60 | No surgery | 58.3 | 40.6 | 30.8 | 18 | <0.001 | 2.93 (2.47–3.48) | 59.4 | 41.9 | 32.2 | 19 | <0.001 | 2.95 (2.48–3.51) |
| Surgery | 88.1 | 78.3 | 71.2 | 75 | 88.7 | 78.8 | 72.3 | 81 | ||||||
| >60 | No surgery | 37.6 | 24.6 | 18.1 | 7 | <0.001 | 3.42 (2.83–4.14) | 35.8 | 22.7 | 16.5 | 6 | <0.001 | 3.13 (2.60–3.76) | |
| Surgery | 80.7 | 71.3 | 61.5 | 61 | 80.7 | 70.1 | 59.4 | 50 | ||||||
| Gender | Female | No surgery | 46.7 | 31.5 | 23.1 | 11 | <0.001 | 3.04 (2.55–3.63) | 48.4 | 33.1 | 25.0 | 11 | <0.001 | 3.14 (2.62–3.77) |
| Surgery | 83.9 | 72.1 | 64.5 | 63 | 84.7 | 73.5 | 66.6 | 71 | ||||||
| Male | No surgery | 45.5 | 30.3 | 23.0 | 9 | <0.001 | 3.30 (2.79–3.91) | 47.0 | 32.1 | 24.3 | 10 | <0.001 | 3.39 (2.86–4.03) | |
| Surgery | 87.0 | 78.8 | 69.9 | 70 | 87.0 | 78.8 | 70.7 | 78 | ||||||
| Tumor site | Head | No surgery | 42.1 | 28.8 | 22.3 | 9 | <0.001 | 2.87 (2.30–3.58) | 43.1 | 30.2 | 23.5 | 9 | <0.001 | 3.03 (2.42–3.80) |
| Surgery | 81.2 | 72.7 | 60.5 | 58 | 82.5 | 75.4 | 64.1 | 63 | ||||||
| Body | No surgery | 46.3 | 28.2 | 21.1 | 10 | <0.001 | 2.29 (1.56–3.37) | 48.4 | 30.5 | 22.9 | 12 | <0.001 | 2.45 (1.64–3.66) | |
| Surgery | 76.0 | 64.0 | 56.0 | 40 | 76.0 | 64.0 | 56.0 | 57 | ||||||
| Tail | No surgery | 51.1 | 35.0 | 26.7 | 13 | <0.001 | 3.25 (2.61–4.05) | 51.6 | 36.1 | 28.1 | 13 | <0.001 | 3.21 (2.57–4.01) | |
| Surgery | 92.5 | 80.5 | 73.9 | 75 | 92.5 | 80.5 | 73.9 | 75 | ||||||
| Tumor size (cm) | ≤4 | No surgery | 46.3 | 30.7 | 24.7 | 11 | <0.001 | 3.26 (2.65–4.02) | 47.7 | 31.9 | 25.7 | 11 | <0.001 | 3.38 (2.74–4.18) |
| Surgery | 82.9 | 77.0 | 67.8 | 71 | 83.9 | 78.9 | 69.4 | 78 | ||||||
| >4 | No surgery | 45.9 | 30.9 | 22.4 | 10 | <0.001 | 3.03 (2.60–3.53) | 47.6 | 32.8 | 24.2 | 11 | <0.001 | 3.14 (2.68–3.67) | |
| Surgery | 87.1 | 74.2 | 66.7 | 63 | 87.1 | 74.2 | 68.1 | 68 | ||||||
| T stage (8th) | I + II | No surgery | 44.6 | 30.0 | 23.4 | 9 | <0.001 | 3.37 (2.56–4.44) | 45.9 | 31.4 | 24.5 | 10 | <0.001 | 3.76 (2.84–4.97) |
| Surgery | 87.5 | 79.0 | 67.9 | 71 | 89.5 | 83.0 | 71.3 | 78 | ||||||
| III + IV | No surgery | 47.6 | 32.1 | 24.0 | 11 | <0.001 | 3.11 (2.67–3.61) | 49.2 | 34.0 | 25.6 | 12 | <0.001 | 3.13 (2.68–3.66) | |
| Surgery | 85.5 | 75.3 | 68.0 | 64 | 85.5 | 75.3 | 68.5 | 70 | ||||||
| LN metastasis | Absent | No surgery | 51.4 | 36.0 | 27.1 | 13 | <0.001 | 3.39 (2.74–4.20) | 52.8 | 37.6 | 28.5 | 14 | <0.001 | 3.45 (2.77–4.29) |
| Surgery | 90.2 | 81.2 | 74.2 | 71 | 90.2 | 81.2 | 75.5 | 75 | ||||||
| Present | No surgery | 44.9 | 29.2 | 22.0 | 10 | <0.001 | 3.04 (2.53–3.65) | 46.5 | 31.1 | 23.8 | 11 | <0.001 | 3.11 (2.57–3.75) | |
| Surgery | 84.2 | 73.1 | 63.7 | 63 | 84.8 | 74.2 | 65.2 | 68 | ||||||
CI, confidence interval; CSS, cancer-specific survival; OS, overall survival; PNET, pancreatic neuroendocrine tumors; other abbreviations as in Table 1.